Rimiducid is a lipid-permeable tacrolimus analogue, homodimerizing an analogue of human protein fkbp12 and binding to wild-type fkbp12 with 1000-fold lower affinity. Rimiducid is a dimerizer agent that acts by cross-linking the FKBP domains. It dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.

FKBP:（EC50）0.1 nM

AP1903, a bivalent 'dimerizer' drug that binds FKBP and induces Fas cross-linking.?A single 2-hour treatment eliminated approximately 80% of T cells, and multiple exposures induced further apoptosis.?T cells were eliminated regardless of their proliferation state, suggesting that the AP1903/Fas system, which contains only human components, is a promising alternative to HSV-tk for treating GVHD[2].

持续的hGH分泌为监测活体内可存活细胞数量提供了一种便捷准确的方法，因为在小鼠中hGH的血清半衰期仅约3分钟。我们连续3天将这些细胞通过肌内(i.m.)植入裸鼠，并通过静脉(i.v.)给予不同剂量的Rimiducid处理这些动物，然后测定血清hGH水平以评估存活细胞的数量。Rimiducid (AP1903; i.v.,0.01, 0.1, 1, 10, 和 100 mg/kg)引发的血清人类GH水平降低呈剂量依赖性，半最大有效剂量为0.4±0.1 mg/kg[1]。